Table.
Demographic characteristics of the study population
|
BNT162b2 |
ChAdOx1 nCoV-19 |
|||
|---|---|---|---|---|
| First dose (N=282 103) | Second dose (N=28 207) | First dose (N=345 280) | ||
| Sex* | ||||
| Female | 173 866 (61·6%) | 19 640 (69·6%) | 199 269 (57·7%) | |
| Male | 108 237 (38·4%) | 8567 (30·4%) | 146 011 (42·3%) | |
| Age, years*† | 62·0 (14·3); 64 (54–72) | 61·0 (17·3); 59 (49–76) | 63·3 (11·5); 65 (59–71) | |
| Body-mass index, kg/m2‡ | 26·8 (5·5) | 26·5 (5·3) | 26·8 (5·3) | |
| Health-care workers* | 31 996 (11·3%) | 8828 (31·3%) | 9746 (2·8%) | |
| Comorbidities* | 77 433 (27·4%) | 7617 (27·0%) | 88 453 (25·6%) | |
| Previous COVID-19* | 14 369 (5·1%) | 2251 (8·0%) | 14 231 (4·1%) | |
| Systemic side-effects | ||||
| Any | 38 155 (13·5%) | 6216 (22·0%) | 116 473 (33·7%) | |
| Headache | 21 910 (7·8%) | 3731 (13·2%) | 78 734 (22·8%) | |
| Fatigue | 23 674 (8·4%) | 4064 (14·4%) | 72 924 (21·1%) | |
| Chills and shiver | 7166 (2·5%) | 1812 (6·4%) | 50 761 (14·7%) | |
| Diarrhoea | 3885 (1·4%) | 416 (1·5%) | 7546 (2·2%) | |
| Fever | 4236 (1·5%) | 1076 (3·8%) | 28 268 (8·2%) | |
| Arthralgia | 9021 (3·2%) | 1978 (7·0%) | 39 648 (11·5%) | |
| Myalgia | 6479 (2·3%) | 1415 (5·0%) | 24 274 (7·0%) | |
| Nausea | 5926 (2·1%) | 981 (3·5%) | 19 509 (5·7%) | |
| Local side-effects§ | ||||
| Any | 150 023 (71·9%) | 9025 (68·5%) | 104 282 (58·7%) | |
| Pain | 61 016 (29·2%) | 4515 (34·3%) | 33 939 (19·1%) | |
| Swelling | 13 264 (6·4%) | 1285 (9·8%) | 9769 (5·5%) | |
| Tenderness | 119 431 (57·2%) | 6705 (50·9%) | 87 609 (49·3%) | |
| Itch | 6242 (3·0%) | 840 (6·4%) | 6934 (3·9%) | |
| Swollen armpit glands | 2278 (1·1%) | 549 (4·2%) | 1994 (1·1%) | |
| Redness | 7891 (3·8%) | 953 (7·2%) | 7431 (4·2%) | |
| Warmth | 14 024 (6·7%) | 1245 (9·4%) | 14 033 (7·9%) | |
| Bruising | 1872 (0·9%) | 64 (0·5%) | 4269 (2·4%) | |
| Allergic reactions | ||||
| Rash | 682 (0·2%) | 103 (0·4%) | 1432 (0·4%) | |
| Skin burning | 2075 (0·7%) | 324 (1·1%) | 5940 (1·7%) | |
| Red welts on face and lips | 469 (0·2%) | 59 (0·2%) | 846 (0·2%) | |
Data are n (%), unless otherwise indicated.
*
p<0·05 for the difference between the first dose of BNT162b2 and the first dose of ChAdOx1 nCoV-19 (Student's t test for continuous variables and χ2 test for categorical variables).
†
Data are mean (SD); median (IQR).
‡
Data are mean (SD).
§
Denominators are 208 767 for the first BNT162b2 dose, 13 179 for the second BNT162b2 dose, and 177 655 for the first ChAdOx1 nCoV-19 dose.